STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #603 by analyst upside · 2026-09-05
KURA
Kura Oncology, Inc.
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+141.5%
implied upside to consensus target
Current Price $13.25
Consensus Target $32.0
Bull Target $76.0
Bear Target $15.0
Analysts Covering 12
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
10
Hold
1
Sell
0
52-Week Low $7.36
52-Week High $13.9
YTD Return +28.2%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.40
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $77M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $7.36
52-Week High $13.9
Current Price $13.25
Bear Target $15.0
Bull Target $76.0
● Now $13.25 ● Target $32.0
TRADING DATA
Avg Volume 1.8M
YTD Return +28.2%
Analyst Count 12
Consensus Buy
Upside to Target +141.5%
Last Updated 2026-09-05

ANALYST SUMMARY

Kura Oncology, Inc. (KURA) is currently trading at $13.25 with a Wall Street consensus price target of $32.0, implying potential upside of 141.5% over the next 12 months. 12 analysts currently cover KURA, with a consensus rating of Buy - 92% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $76.0, while the most cautious has a target of $15.0.

KURA operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 28.2% year-to-date and is currently trading near the upper end of its 52-week range of $7.36 – $13.9.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for KURA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-08-24 Building track record
Wedbush - Reiterated
Outperform → Outperform 2026-08-13 Building track record
Wedbush reit
Outperform → Outperform 2026-07-28 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-06-15 Building track record
Lake Street ● Initiated
Buy 2026-04-14 27% win rate (11 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-03-24 Building track record
UBS - Reiterated
Buy → Buy 2026-03-13 33% win rate (6 calls)
Wedbush - Reiterated
Outperform → Outperform 2026-03-06 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
42
out of 100
Coverage depth
20/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →